Trials / Not Yet Recruiting
Not Yet RecruitingNCT06385431
Obeservational Cohort for Evaluating Future Cardiovascular Disease With High Metabolic Risks
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 8,000 (estimated)
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
Cardiovascular and metabolic diseases refer to a large category of cardiovascular diseases accompanied by a series of metabolic disorders (including dyslipidemia, obesity, abnormal glucose tolerance, diabetes, hypertension, thyroid dysfunction, etc.), which is the primary cause of death and disease burden of Chinese residents.The number of deaths from atherosclerotic cardiovascular disease (ASCVD) in China is about 2.4 million, accounting for 61% of the total cardiovascular deaths, accounting for more than 40% of the all-cause deaths. In Chinese patients with coronary heart disease, 52.9% are complicated with diabetes.Despite the 1.1 million coronary stents implanted in China, there has been no reduction in cardiovascular mortality, which highlights the importance of threshold advancement and the management of metabolic risk factors. In recent years, the new concept of cardiovascular and metabolic diseases has been actively promoted at home and abroad, and the focus of prevention and treatment strategy of cardiovascular and metabolic diseases has been called for.The project proposed the concept of co-treatment of metabolic diseases based on disorders of blood pressure regulation, disorders of glucose metabolism and disorders of lipid metabolism. Subjects eligible for cardiovascular and metabolic diseases were screened, their past medical records were registered, education and diagnosis and treatment management were conducted.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | observational study | obeservational study with none intervention |
Timeline
- Start date
- 2024-04-28
- Primary completion
- 2026-04-30
- Completion
- 2026-04-30
- First posted
- 2024-04-26
- Last updated
- 2024-04-26
Source: ClinicalTrials.gov record NCT06385431. Inclusion in this directory is not an endorsement.